B.O.S.S. Retirement Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 15.9% in the 2nd quarter, Holdings Channel reports. The fund owned 766 shares of the company’s stock after purchasing an additional 105 shares during the period. B.O.S.S. Retirement Advisors LLC’s holdings in Eli Lilly and Company were worth $597,000 at the end of the most recent quarter.
A number of other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. raised its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Nuveen LLC bought a new position in Eli Lilly and Company during the 1st quarter worth approximately $4,613,912,000. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC grew its position in shares of Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after buying an additional 773,947 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Insider Buying and Selling
In other news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Trading Up 8.2%
Shares of LLY stock opened at $825.92 on Thursday. The company has a market capitalization of $781.70 billion, a P/E ratio of 53.98, a P/E/G ratio of 1.06 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The firm has a 50-day moving average price of $733.71 and a 200 day moving average price of $766.37.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- P/E Ratio Calculation: How to Assess Stocks
- Datavault AI: The New AI Contender Backed by Big Funding
- What Makes a Stock a Good Dividend Stock?
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- Industrial Products Stocks Investing
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.